FACTANKER

US-Listed In Vitro & In Vivo Diagnostic Substances — EBITDA Margin Percentiles, FY 2020

Population: 14 US-listed companies (SIC 2835), fiscal year 2020; fiscal year ends 2020-09-30 to 2021-05-31.

Fiscal year: 2019 · 2020 · 2021 · 2022 · 2023 · 2024 · 2025 · latest

10th percentile-334.0%
25th percentile-88.4%
Median13.0%
75th percentile27.8%
90th percentile55.6%
Mean-92.2%
Minimum-801.1%
Maximum66.8%
Methodology & sources
EBITDA margin = (operating income + depreciation & amortization) / revenue, all values as filed; computed in SQL per company, then percentiles. Fiscal year 2020 = fiscal years ending 2020-06-01 to 2021-05-31 (majority-overlap rule; June-ending fiscal years count toward the ending calendar year).
Source: SEC EDGAR filings (public domain). Data: FACTANKER registry, precomputed 2026-09-03.

Evidence samples

Latest EBITDA Margin percentiles (live) · All In Vitro & In Vivo Diagnostic Substances benchmarks · All industries

Cite as: FACTANKER, https://factanker.com/industries/sic-2835/ebitda-margin/2020